Colonic Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In RAS-BRAF wild type left colon tumors, Turkish oncologists mostly use chemotherapy and anti-EGFR therapy (90.1%) for the first-line treatment, while on the right side, oncologists favored anti-VEGF therapy in combination with chemotherapy (65.5%).
|
30941953 |
2019 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Colon tumors with RNF43-G659Vfs*41 had low Wnt/β-catenin signaling and were frequently mutated in BRAF.
|
31811196 |
2019 |
Colonic Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In proximal colon cancer, tumor biomarkers tended to be correlated with each other, and MSI and BRAF mutation functioned as key molecular characteristics during the carcinogenesis.
|
28623901 |
2017 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
BRAF-mutant metastatic colorectal cancers (mCRCs) share many clinicopathologic features with right-sided colon tumors, including frequent peritoneal involvement.
|
27956538 |
2016 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Additionally, 13 miRNAS were differentially expressed for KRAS-mutated rectal tumors, 8 differentially expressed miRNAs for colon CIMP high tumors, and 2 differentially expressed miRNAs for BRAF-mutated colon tumors.
|
27198570 |
2016 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In addition, these mutations are associated with specific anatomical area in colon tumor development, as BRAF mutations with the microsatellite instability (MSI).
|
23572025 |
2013 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Right-sided colon tumors more frequently have BRAF (p.V600E) mutations and have higher methylation grades when compared to left-sided malignancies.
|
24244575 |
2013 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
CLINVAR |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
|
22281684 |
2012 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.
|
22281684 |
2012 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These results reveal a novel molecular characteristic of colon tumours containing Ras or B-RAF mutations and should help in defining new targets for cancer therapy.
|
19700418 |
2009 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our data reveal that oncogenic KRAS and BRAF mutations differentially regulate the hypoxic induction of HIF-1alpha and HIF-2alpha in colon cancer, and this may potentially contribute to the phenotypic differences of KRAS and BRAF mutations in colon tumors.
|
19843849 |
2009 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
LHGDN |
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.
|
18519771 |
2008 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These results reveal a novel molecular characteristic of colon tumors containing B-Raf mutations and should help in defining novel targets for cancer therapy.
|
18602919 |
2008 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A priori screening of colon tumors for PTEN expression status and PIK3CA and Ras/BRAF mutation status could help stratify patients likely to benefit from this therapy.
|
18339877 |
2008 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
LHGDN |
Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.
|
17148775 |
2006 |
Colonic Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation.
|
14695993 |
2004 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In this study, we examined the effect of colon tumor-associated mutations within the B-Raf glycine-rich loop (G loop) on MEK/Erk and NFkappaB signaling and on the transformation of NIH3T3 fibroblasts or IEC-6 intestinal epithelial cells.
|
15150094 |
2004 |
Colonic Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Here, we examined the effect of colon tumor-associated B-Raf mutations within the kinase activation segment, including V599E, on extracellular signal-regulated kinase (Erk) and nuclear factor kappaB (NFkappaB) signaling, and on the transformation of NIH3T3 fibroblasts.
|
14678966 |
2003 |